Short-term androgen deprivation therapy and high-dose radiotherapy in intermediate- and high-risk localized prostate cancer: Results from the GETUG 14 randomized phase III trial

Authors :: Demogeot, N.
Sargos, P.
Sahki, N.
Guérif, S.
De Crevoisier, R.
Calais, G.
Hannoun Levi, J.M.
Bouche, G.
Hennequin, C.
Cretin, J.
Belkacemi, Y.
Khalifa, J.
Azria, D.
Grandgirard, A.
Pommier, P.
Simon, J.M.
Leger, C.
Beckendorf, V.
Dubray, B.
Supiot, S.
Source :: Progrès en Urologie - FMC; November 2024, Vol. 34 Issue: 7, Number 7 Supplement 1 pS36-S36, 1p
Publication Year :: 2024
Abstract: Few studies compared short-term androgen deprivation (STADT) with high-dose radiotherapy (STADT-RT) versus high dose radiotherapy (RT) alone in localized prostate cancer.

Full Text Access

Tools